Skip to main content
METabolic EXplorer logo

METabolic EXplorer — Investor Relations & Filings

Ticker · METEX ISIN · FR0004177046 LEI · 969500VI1GSBPGD9B460 PA Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2016-12-13 Declaration of Voting R…
Country FR France
Listing PA METEX

About METabolic EXplorer

https://www.metabolic-explorer.com/

METabolic EXplorer (METEX) is an industrial biotechnology company specializing in the development and industrialization of fermentation bioprocesses. The company produces functional ingredients and chemical intermediates from renewable, non-food raw materials, offering sustainable alternatives to petrochemical processes. Its portfolio is centered on three main product families: 1,3-propanediol (PDO) for cosmetics, liquid polymers, and textiles; butyric acid (BA) for animal nutrition and the flavors and fragrances market; and amino acids for animal feed. The company operates through its subsidiaries, METEX NØØVISTA, which manages the PDO and BA production, and METEX NØØVISTAGO, which focuses on amino acids and ingredients for animal nutrition.

Recent filings

Filing Released Lang Actions
Déclaration du nombre total de Droits de Vote et d'Actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Déclaration du nombre total de Droits de Vote et d'Actions composant le capital social" (Declaration of the total number of Voting Rights and Shares comprising the share capital) and references Article 223-16 of the AMF general regulation. It provides a breakdown of total shares, theoretical voting rights, treasury shares (autodétention), and exercisable voting rights as of a specific date (30/11/2016). This content directly relates to the official declaration of voting rights and share structure, which aligns precisely with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is short and contains the declaration itself, not an announcement of a separate report.
2016-12-13 French
Cession à Evonik de la technologie de METEX pour la production par fermentation de méthionine
M&A Activity Classification · 99% confidence The document is a press release dated December 7, 2016, announcing the finalization of the sale of METEX's methionine fermentation technology to Evonik for a fixed amount plus future service payments. It details the financial impact (cash position) and mentions future strategic plans, including presenting the strategic plan during the annual results presentation on March 28, 2017. This is a specific corporate announcement regarding a major transaction (divestiture/sale of technology and assets) and its immediate financial consequences, rather than a standard periodic financial report (like 10-K or IR) or a general regulatory filing (RNS). Since there is no specific category for 'Asset Sale Announcement', the closest fit among the provided options that covers significant corporate/financing activities is 'Capital/Financing Update' (CAP), as the transaction significantly alters the company's capital structure and cash position. However, given the nature of the announcement (a major business transaction/divestiture), it is most accurately classified as a significant corporate event announcement. Since 'M&A Activity' (TAR) is defined as 'merger proposals or takeover bids', this divestiture doesn't fit perfectly. Given the options, and recognizing this is a major, non-routine business event announcement, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standard corporate news releases that don't fit the other specific financial reporting codes, although 'CAP' is a close second due to the cash impact. Given the context of a major business transaction announcement, RNS is the most appropriate fallback for specific corporate news not covered elsewhere.
2016-12-07 French
Transfer of METEX technology for the fermentative production of methionine to Evonik
M&A Activity Classification · 99% confidence The document is a press release dated December 7, 2016, announcing the completion of a technology transfer deal between METEX and Evonik for EUR 40 million plus potential future payments. It details a significant corporate transaction (asset sale/licensing) and its immediate impact on the company's cash position and future strategy (industrialization of PDO and MPG). This type of announcement, detailing financing, capital structure changes, or major corporate transactions outside of standard periodic reporting (like 10-K or IR), best fits the 'Capital/Financing Update' category, as it directly relates to a major cash inflow and strategic realignment based on that transaction. It is not a standard earnings release (ER), an interim report (IR), or a formal M&A announcement (TAR), but rather a specific financial/corporate event update. Given the focus on the cash received and the strategic implications, CAP is the most appropriate fit.
2016-12-07 English
Evonik to acquire technology from METEX for the fermentative production of methionine
M&A Activity Classification · 99% confidence The document is a press release announcing a specific corporate transaction: Evonik acquiring technology from METEX for methionine production. This type of announcement, detailing a strategic acquisition, financing consideration (€45 million), and future cooperation plans, is characteristic of a major corporate event announcement. It is not a periodic financial report (like 10-K or IR), an earnings release (ER), or a transcript (CT). Since it details a significant corporate action involving financing/capital structure changes (the acquisition consideration), the 'Capital/Financing Update' (CAP) is a strong candidate, although 'Regulatory Filings' (RNS) is often used for general press releases. However, given the focus on the acquisition and the associated payment, it fits best under a category related to corporate transactions or financing updates. Since there isn't a specific 'M&A Announcement' code, and this is a definitive agreement announcement rather than a general regulatory filing, I will check the closest fit. The transaction involves a significant cash outlay (€45 million) for technology acquisition, which strongly relates to capital deployment. If the focus were purely on the M&A structure, TAR might apply, but this is more about the financing/acquisition of an asset. Given the options, and recognizing this is a definitive announcement of a strategic transaction, it most closely aligns with a significant corporate event. Since it is a definitive agreement announcement and not a standard periodic report, and it involves a large cash consideration, I will classify it as a general Regulatory Filing (RNS) as it is a press release announcing a material event, which often falls into the RNS bucket when a specific M&A code is not explicitly defined for the announcement phase, or CAP if the financing aspect is prioritized. Given the context of M&A activity (TAR), this is a strong candidate, but TAR is defined as 'Merger Proposals or Takeover Bids'. This is an asset acquisition. Therefore, RNS (General Regulatory Filings/Announcements) is the most appropriate fallback for a material press release that doesn't fit the specific financial report codes.
2016-11-28 English
Evonik va acquérir la technologie de METEX pour la production par fermentation de méthionine
M&A Activity Classification · 99% confidence The document text describes an agreement between Evonik and METEX for the acquisition of fermentation technology for methionine production. This is a corporate action announcement detailing a transaction, including financial terms (€45 million) and strategic rationale. This type of announcement, detailing financing, M&A activity, or significant corporate transactions, best fits the 'Capital/Financing Update' (CAP) or 'M&A Activity' (TAR) categories. Since the core event is the acquisition of technology/assets, 'TAR' (Merger/Takeover/Transaction Activity) is the most precise fit, although 'CAP' could also apply if viewed as a strategic investment/financing move. Given the explicit description of one company acquiring technology from another, TAR is selected. The document is a press release format, not a formal regulatory filing like 10-K or IR, and it is not a short announcement of a report (ruling 2 does not apply).
2016-11-28 French
Information financière du 3ème trimestre 2016
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial update from METabolic EXplorer for the 3rd quarter of 2016. It contains specific financial data, including revenue figures, cash position, and net debt, presented in a table and narrative format. Since it provides substantive financial data for a period shorter than a full fiscal year, it qualifies as an Interim/Quarterly Report (IR). Q3 2016
2016-11-15 French

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.